PMCB - PharmaCyte Biotech to reverse split shares 1:1500

PharmaCyte Biotech (PMCB) will effect a 1-for-1,500 reverse stock split of its common shares, leaving the company with only about 1.6M issued and outstanding shares from ~2.4B shares.Trading on reverse split-adjusted basis will commence at the opening of the market on July 12, 2021. “With approximately 1.6 million shares outstanding, we believe this change will make it easier for investors to trade in our stock and is a necessary step before the Company’s common stock can be listed on a national stock exchange like Nasdaq, which is our expectation,” stated Kenneth L. Waggoner, CEO. “We believe the reverse stock split will assist the Company in pursuing additional financing activities and/or other strategic transactions to support the development of our product candidates,” Waggoner continued.

For further details see:

PharmaCyte Biotech to reverse split shares 1:1,500